Ann: Phase I Canine Repeat Dose MPL Demonstrates High Performance, page-14

Very interesting, and that's for a pain killer. What will PAA be worth if MPL can decisively prove itself as a low toxicity, broad spectrum cancer treatment that successfully treats aggressive late stage "refractory" or resistant tumours that are usually regarded as terminal?

And then of course, there are the analogues that are yet to be fully explored and the non cancer possibilities of this mTor mechanism drug, like, say use in transplants or whatever that mTor drugs are used in?. hmmmmmm*

Peeteepoo's link again:
https://endpts.com/canine-club-elanco-animal-health-makes-takeover-play-for-partner-aratana-in-up-to-245m-deal/

* This stock is still a spec. Everything I said may turn out wrong. Don't be crazy in your allocations. DYOR

GLTAH